198 related articles for article (PubMed ID: 11341356)
1. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides.
Lin S; Hirschowitz SL; Williams C; Shintako P; Said J; Rao JY
Cancer Detect Prev; 2001; 25(2):202-9. PubMed ID: 11341356
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens.
Cheng L; Reiter RE; Jin Y; Sharon H; Wieder J; Lane TF; Rao J
J Urol; 2003 Jun; 169(6):2094-100. PubMed ID: 12771726
[TBL] [Abstract][Full Text] [Related]
3. [Value of CK20 immunocytochemistry as an adjuvant to urine liquid-based cytology in detection of urothelial carcinoma].
Li M; Li HX; Guo HQ; Zhao H; Zhao LL; Ma JH; Li CL; Cao J; Pan QJ
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):669-73. PubMed ID: 23159079
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma.
Bhatia A; Dey P; Kumar Y; Gautam U; Kakkar N; Srinivasan R; Nijhawan R
Cytopathology; 2007 Apr; 18(2):84-6. PubMed ID: 17397492
[TBL] [Abstract][Full Text] [Related]
5. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
[TBL] [Abstract][Full Text] [Related]
6. The simultaneous use of telomerase, cytokeratin 20 and CD4 for bladder cancer detection in urine.
Siracusano S; Niccolini B; Knez R; Tiberio A; Benedetti E; Bonin S; Ciciliato S; Pappagallo GL; Belgrano E; Stanta G
Eur Urol; 2005 Mar; 47(3):327-33. PubMed ID: 15716196
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma.
Srivastava R; Arora VK; Aggarwal S; Bhatia A; Singh N; Agrawal V
Diagn Cytopathol; 2012 Sep; 40(9):755-9. PubMed ID: 22888081
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
[TBL] [Abstract][Full Text] [Related]
9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
10. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.
Eissa S; Kassim SK; Labib RA; El-Khouly IM; Ghaffer TM; Sadek M; Razek OA; El-Ahmady O
Cancer; 2005 Apr; 103(7):1356-62. PubMed ID: 15717321
[TBL] [Abstract][Full Text] [Related]
11. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
13. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer.
Golijanin D; Shapiro A; Pode D
J Urol; 2000 Dec; 164(6):1922-5. PubMed ID: 11061882
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder.
Melissourgos ND; Kastrinakis NG; Skolarikos A; Pappa M; Vassilakis G; Gorgoulis VG; Salla C
Urology; 2005 Sep; 66(3):536-41. PubMed ID: 16140073
[TBL] [Abstract][Full Text] [Related]
16. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
18. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
Whisnant RE; Bastacky SI; Ohori NP
Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
[TBL] [Abstract][Full Text] [Related]
19. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
